Difficulty: Medium
Average Score: 64%
Practice
Which of the following pairs of preparations has been studied for bioequivalence?
Correct answer
C
Rationale
In this Endocrine Pharmacology Quiz question, the correct answer is option C) Levothroid - Synthroid. These two preparations have been studied for bioequivalence, meaning they have demonstrated similar pharmacokinetic and pharmacodynamic properties in the body. This is crucial in ensuring that patients can switch between these medications without experiencing differences in efficacy or safety.
Option A) Levoxyl-Thyrolar is incorrect because Levoxyl is a branded form of levothyroxine while Thyrolar is a combination thyroid hormone product containing both T3 and T4. These two medications are not bioequivalent as they contain different active ingredients and ratios.
Option B) Thyroglobulin - Proloid is also incorrect as Thyroglobulin is a protein produced by the thyroid gland and has a different mechanism of action compared to Proloid, which is a thyroid hormone replacement therapy. These two are not studied for bioequivalence.
Option D) Cytomel - Synthroid is incorrect because Cytomel contains liothyronine (T3) while Synthroid contains levothyroxine (T4). These two medications have different active ingredients and are not considered bioequivalent.
Understanding bioequivalence in pharmacology is crucial for healthcare professionals to make informed decisions when selecting medications for patients. It ensures consistency in therapeutic effects and minimizes the risk of adverse events due to differences in drug formulations. This knowledge is essential for pharmacists, doctors, and nurses involved in managing patients with endocrine disorders requiring thyroid hormone replacement therapy.
Option A) Levoxyl-Thyrolar is incorrect because Levoxyl is a branded form of levothyroxine while Thyrolar is a combination thyroid hormone product containing both T3 and T4. These two medications are not bioequivalent as they contain different active ingredients and ratios.
Option B) Thyroglobulin - Proloid is also incorrect as Thyroglobulin is a protein produced by the thyroid gland and has a different mechanism of action compared to Proloid, which is a thyroid hormone replacement therapy. These two are not studied for bioequivalence.
Option D) Cytomel - Synthroid is incorrect because Cytomel contains liothyronine (T3) while Synthroid contains levothyroxine (T4). These two medications have different active ingredients and are not considered bioequivalent.
Understanding bioequivalence in pharmacology is crucial for healthcare professionals to make informed decisions when selecting medications for patients. It ensures consistency in therapeutic effects and minimizes the risk of adverse events due to differences in drug formulations. This knowledge is essential for pharmacists, doctors, and nurses involved in managing patients with endocrine disorders requiring thyroid hormone replacement therapy.